NCT06933134View on ClinicalTrials.gov

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Rheumatoid Arthritis (RA)
Trial Locations (1)

37044

University hospital, Tours

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT06933134 - Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter